ArticleJournal of translational medicine2025
Comprehensive genomic profiling of breast cancer reveals mutational landscape and the PEEKABOO model: a population-specific assessment tool for predicting germline mutations.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGermline mutations in cancer-predisposition genes are critical for clinical risk assessment and therapeutic decisions in breast cancer, yet large-scale genomic studies and population-specific tools remain limited for Asian populations.
methodsIn this prospective clinic-based cohort study, 2700 unselected Chinese breast cancer patients underwent germline sequencing for single nucleotide variations, insertion/deletions, and large genomic rearrangements using a clinically validated 32-gene panel. Multiplex ligation-dependent probe amplification was used for confirmation of copy number variations. A multivariate logistic regression model (PEEKABOO) was developed to predict mutation probability. Therapeutic impact was assessed in 632 patients receiving neoadjuvant therapy.
resultsThe overall prevalence of deleterious germline variants was 11.4%, predominantly BRCA2 (3.7%) and BRCA1 (3.1%) with protein-truncating variants accounting for 81.8% of alterations. Mutation prevalence progressively increased across hereditary risk tiers: 4.9% for the NeoFHS-zero group, 13.1% for the NeoFHS-low group, and 19.9% for the NeoFHS-high group (p < 0.001). In HER2-negative breast cancer, germline homologous recombination repair gene mutations (gHRRm) independently predicted higher pathological complete response (pCR) rates (OR, 2.24; 95% CI, 1.09-4.66; p = 0.028). A numerically higher pCR rate was observed in gHRR-mutant TNBC patients receiving neoadjuvant immunotherapy combined with chemotherapy (80.0% vs 55.6%, p = 0.6). The PEEKABOO model exhibited strong performance in predicting mutation probability in both panel genes (area under curve [AUC], 0.73; accuracy, 57%; sensitivity/specificity, 76%/54%; PPV/NPV, 17%/95%) and BRCA1/2 (AUC, 0.80; accuracy, 62%; sensitivity/specificity, 81%/61%; PPV/NPV, 13%/98%).
conclusionsOur study establishes a unique germline mutation profile of Chinese breast cancer in a large-scale targeted sequencing cohort. Germline HRR gene mutation status is a potential biomarker for response to neoadjuvant treatment with DNA-damaging chemotherapeutics for HER2-negative breast cancer. The population-specific PEEKABOO model improves the predictive efficiency of germline mutations and represents a clinically applicable tool for risk stratification in Chinese patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.